MTOR and lung cancer: In this section, we describe PI3K pathway inhibitors that have reached clinical trials for the treatment of lung cancer, considering four different categories: PI3K inhibitors, dual PI3K- mTOR inhibitors, Akt inhibitors and mTOR inhibitors.